HRP20010904A2 - Polymorphs of a crystalline azabicyclo[2,2,2]octan-3-amine citrate and their pharmaceutical compositions - Google Patents

Polymorphs of a crystalline azabicyclo[2,2,2]octan-3-amine citrate and their pharmaceutical compositions Download PDF

Info

Publication number
HRP20010904A2
HRP20010904A2 HR20010904A HRP20010904A HRP20010904A2 HR P20010904 A2 HRP20010904 A2 HR P20010904A2 HR 20010904 A HR20010904 A HR 20010904A HR P20010904 A HRP20010904 A HR P20010904A HR P20010904 A2 HRP20010904 A2 HR P20010904A2
Authority
HR
Croatia
Prior art keywords
polymorphic form
approximately
citrate
crystalline
hours
Prior art date
Application number
HR20010904A
Other languages
English (en)
Croatian (hr)
Inventor
Michael James Castaldi
George Joseph Quallich
Lewin Theophilus Wint
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HRP20010904A2 publication Critical patent/HRP20010904A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20010904A 1999-06-01 2000-05-18 Polymorphs of a crystalline azabicyclo[2,2,2]octan-3-amine citrate and their pharmaceutical compositions HRP20010904A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13699299P 1999-06-01 1999-06-01
PCT/IB2000/000665 WO2000073304A1 (en) 1999-06-01 2000-05-18 Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HRP20010904A2 true HRP20010904A2 (en) 2003-02-28

Family

ID=22475338

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010904A HRP20010904A2 (en) 1999-06-01 2000-05-18 Polymorphs of a crystalline azabicyclo[2,2,2]octan-3-amine citrate and their pharmaceutical compositions

Country Status (48)

Country Link
US (1) US6255320B1 (cs)
EP (1) EP1181290B1 (cs)
JP (1) JP3830816B2 (cs)
KR (1) KR100476606B1 (cs)
CN (1) CN1146565C (cs)
AP (1) AP2001002349A0 (cs)
AR (1) AR033331A1 (cs)
AT (1) ATE244239T1 (cs)
AU (1) AU767334B2 (cs)
BG (1) BG65240B1 (cs)
BR (1) BR0011094A (cs)
CA (1) CA2372238C (cs)
CO (1) CO5170463A1 (cs)
CY (1) CY2007011I2 (cs)
CZ (1) CZ295819B6 (cs)
DE (1) DE60003679T2 (cs)
DK (1) DK1181290T3 (cs)
DZ (1) DZ3050A1 (cs)
EA (1) EA003731B1 (cs)
EC (1) ECSP003508A (cs)
EE (1) EE200100656A (cs)
ES (1) ES2199825T3 (cs)
GT (1) GT200000087A (cs)
HN (1) HN2000000077A (cs)
HR (1) HRP20010904A2 (cs)
HU (1) HUP0201301A3 (cs)
IL (1) IL146406A0 (cs)
MA (1) MA26742A1 (cs)
MX (1) MXPA01012325A (cs)
MY (1) MY133508A (cs)
NO (1) NO20015848L (cs)
NZ (1) NZ515349A (cs)
OA (1) OA11956A (cs)
PA (1) PA8496101A1 (cs)
PE (1) PE20010209A1 (cs)
PL (1) PL196046B1 (cs)
PT (1) PT1181290E (cs)
SI (1) SI1181290T1 (cs)
SK (1) SK285820B6 (cs)
SV (1) SV2001000093A (cs)
TN (1) TNSN00120A1 (cs)
TR (1) TR200103473T2 (cs)
TW (1) TWI285204B (cs)
UA (1) UA66925C2 (cs)
UY (1) UY26176A1 (cs)
WO (1) WO2000073304A1 (cs)
YU (1) YU81101A (cs)
ZA (1) ZA200109775B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554908A1 (en) * 2004-01-30 2005-09-09 Pfizer Products Inc. Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
AU2005216706B2 (en) * 2004-01-30 2007-11-29 Pfizer Products Inc. NK-1 receptor antagonists anesthesia recovery
NZ548236A (en) * 2004-01-30 2010-02-26 Pfizer Prod Inc Compositions comprising (2S.3S) (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-alkyl-2-methoxy-benzyl)-amine derivatives
BRPI0507334A (pt) * 2004-02-02 2007-07-03 Pfizer Prod Inc processo para a preparação de -1(2s,3s)-2-benzidril-n-(5-terc-butil-2-metoxibenzila)q uinuclidin-3-amina
MX361286B (es) * 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法
CN112979639B (zh) * 2019-12-16 2025-08-08 凯默斯医药科技(上海)有限公司 一种马罗皮坦新晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021677A1 (en) * 1991-05-31 1992-12-10 Pfizer Inc. bibNUCLIDINE DERIVATIVES
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis

Also Published As

Publication number Publication date
BG106204A (en) 2002-07-31
SK285820B6 (sk) 2007-09-06
TNSN00120A1 (fr) 2005-11-10
WO2000073304A1 (en) 2000-12-07
EA003731B1 (ru) 2003-08-28
UY26176A1 (es) 2000-12-29
DE60003679T2 (de) 2004-05-27
HUP0201301A2 (en) 2002-08-28
PL196046B1 (pl) 2007-11-30
CA2372238A1 (en) 2000-12-07
SK17332001A3 (sk) 2002-07-02
YU81101A (sh) 2004-07-15
NZ515349A (en) 2004-03-26
CN1146565C (zh) 2004-04-21
AU4424800A (en) 2000-12-18
SV2001000093A (es) 2001-11-08
ZA200109775B (en) 2002-11-28
ES2199825T3 (es) 2004-03-01
PL352716A1 (en) 2003-09-08
AP2001002349A0 (en) 2001-12-31
KR20020010688A (ko) 2002-02-04
UA66925C2 (uk) 2004-06-15
CY2007011I1 (el) 2010-07-28
EP1181290B1 (en) 2003-07-02
AU767334B2 (en) 2003-11-06
PA8496101A1 (es) 2002-07-30
KR100476606B1 (ko) 2005-03-18
PT1181290E (pt) 2003-09-30
CA2372238C (en) 2006-12-19
CY2007011I2 (el) 2010-07-28
JP2003501354A (ja) 2003-01-14
DZ3050A1 (fr) 2004-03-27
IL146406A0 (en) 2002-07-25
MXPA01012325A (es) 2002-07-22
EA200101108A1 (ru) 2002-04-25
EP1181290A1 (en) 2002-02-27
CN1353711A (zh) 2002-06-12
DE60003679D1 (de) 2003-08-07
BG65240B1 (bg) 2007-09-28
CO5170463A1 (es) 2002-06-27
HK1046284A1 (en) 2003-01-03
JP3830816B2 (ja) 2006-10-11
MA26742A1 (fr) 2004-12-20
US6255320B1 (en) 2001-07-03
HUP0201301A3 (en) 2002-10-28
AR033331A1 (es) 2003-12-17
TWI285204B (en) 2007-08-11
BR0011094A (pt) 2002-03-19
CZ295819B6 (cs) 2005-11-16
OA11956A (en) 2006-04-13
NO20015848D0 (no) 2001-11-30
DK1181290T3 (da) 2003-09-29
CZ20014269A3 (cs) 2002-04-17
TR200103473T2 (tr) 2002-04-22
EE200100656A (et) 2003-02-17
SI1181290T1 (en) 2003-12-31
PE20010209A1 (es) 2001-03-01
ATE244239T1 (de) 2003-07-15
HN2000000077A (es) 2001-02-02
ECSP003508A (es) 2002-02-25
MY133508A (en) 2007-11-30
NO20015848L (no) 2001-12-18
GT200000087A (es) 2001-11-22

Similar Documents

Publication Publication Date Title
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
HRP20010904A2 (en) Polymorphs of a crystalline azabicyclo[2,2,2]octan-3-amine citrate and their pharmaceutical compositions
HRP20010920A2 (en) Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists
US6387925B1 (en) Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
HK1046284B (en) Polymorphs of crystalline azabicyclo(2,2,2) octan-3-aminecitrate and their pharmaceutical compositions

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20040407

Year of fee payment: 5

OBST Application withdrawn